Valuation: InspireMD

Market Cap 32.02M 28.12M 26.15M 24M 45.09M 3.08B 45.78M 311M 121M 1.52B 120M 118M 5.24B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 32.02M 28.12M 26.15M 24M 45.09M 3.08B 45.78M 311M 121M 1.52B 120M 118M 5.24B EV / Sales 2026 *
3.09x
EV / Sales 2027 * 1.46x
Free-Float
80.17%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 31/12/2019
Director of Finance/CFO 58 24/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 01/06/2017
Director/Board Member 68 06/02/2013
Director/Board Member 62 31/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-3.81%+32.01% - - 32.55M
+3.54%-0.29%-17.63%+11.73% 122B
+1.92%-1.98%-1.60%-5.28% 12.52B
+0.95%-1.16%+59.98%+105.16% 8.93B
-6.12%+1.09%-46.50%-69.18% 4.67B
-0.21%-8.81%+0.67%+38.46% 2.63B
-2.59%-5.52%-12.69%-24.30% 1.63B
-3.05%-8.72%-25.24%-33.61% 1.63B
+3.72%-3.71%-2.42%-58.55% 1.5B
Average -0.63%-3.92%-5.68%-4.45% 19.47B
Weighted average by Cap. +2.78%-3.64%-12.33%+12.21%

Financials

2026 *2027 *
Net sales 10.38M 9.11M 8.47M 7.78M 14.61M 999M 14.84M 101M 39.32M 491M 38.95M 38.11M 1.7B 21.92M 19.25M 17.9M 16.43M 30.86M 2.11B 31.34M 213M 83.05M 1.04B 82.27M 80.5M 3.59B
Net income - -
Net Debt - -
Logo InspireMD
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
-